SNPX - Cutting-Edge Cannabis Products On The Horizon As Biotech Co. Funds New Research | Benzinga
Synaptogenix, Inc. (NASDAQ: SNPX) has teamed up with Cannasoul Analytics Ltd. a company founded by the Technion Research & Development Foundation and world-renowned cannabis key opinion leader and researcher Professor Dedi Meiri of The Technion
The New York-based biopharmaceutical company developing therapeutics for neurodegenerative disorders and approximately $33 million in cash as of June 30, 2023, aims to support research and development of pharmaceutical therapeutics.
Under terms of the investment agreement, Synaptogenix obtained a preemptive right to fund the further research and commercialization of certain intellectual property, technology, and future products developed by Cannasoul and licensed from The Technion.
Professor Peretz Lavie, 16th president of the Technion and Cannasoul board member, praised the new collaboration.
See also: Hebrew University, Cannabis Accelerator Collaborate To Advance Medical Marijuana Research
"Cannasoul is pleased to welcome Synaptogenix as a key partner in our development of groundbreaking therapeutics derived from natural ...